Table 2

Treatment related characteristics associated with non-cure after anti-tuberculosis treatment in patients diagnosed in 30 remote and poor counties in Shaanxi province, China

Treatment characteristic

n(%)

Treatment result

OR

95% CI

p-value


Uncured (%)

Cured (%)


Co-morbidity

< 0.01

No

562 (93.0)

95 (16.9)

467 (83.1)

1

Yes

42 (7.0)

22 (52.4)

20 (47.6)

5.41

2.84-10.30

Fever

0.04

No

426 (66.7)

99(23.9)

327 (76.1)

1

Yes

213 (33.3)

34 (16.0)

179 (84.0)

1.59

1.04-2.45

Loss of appetite

< 0.01

No

497 (77.8)

92 (18.5)

405 (81.5)

Yes

142 (22.2)

41 (28.9)

101 (71.1)

1.79

1.17-2.74

Institute where TB was diagnosed

0.01

CDC

142 (22.2)

60 (17.1)

290 (82.9)

1

Other

497 (77.8)

73 (25.3)

216 (74.7)

1.63

1.11-2.40

DOT supervisor

< 0.01

No supervisor

169 (26.4)

48 (28.4)

121 (71.6)

1

Family

367 (57.4)

73 (19.9)

294 (80.1)

0.63

0.41-0.95

Doctor

103 (16.1)

12 (11.7)

91 (88.3)

0.33

0.17-0.66

Number of times forgotten to take drugs

< 0.01

none

541 (84.7)

104 (19.2)

437 (80.8)

1

≤9 times

76 (11.9)

18 (23.7)

58 (76.3)

1.30

0.74-2.31

>9 times

22 (3.4)

11 (50.0)

11 (50.0)

4.20

1.77-9.96

Maximum number of subsequently missed doses

0.01

None

542 (84.8)

105 (19.4)

437 (80.6)

1

≤ 3 times

64 (10.0)

14 (21.9)

50 (78.1)

1.17

0.62-2.19

>3 times

33 (5.2)

14 (42.4)

19 (57.6)

3.07

1.49-6.32

Interruption of treament

< 0.01

No

591 (92.5)

102 (17.3)

489 (82.7)

1

Yes

48 (7.5)

31 (64.6)

17 (35.4)

8.74

4.66-16.40

Severity of side effects*

< 0.01

None

361 (56.5)

66 (18.3)

295 (81.7)

1

Severe

54 (8.5)

27 (50.0)

27 (50.0)

4.47

2.46-8.12

Medium

41 (6.4)

14 (34.1)

27 (65.9)

2.32

1.15-4.66

Light

183 (28.6)

26 (14.2)

157 (85.8)

0.74

0.45-1.21

Sputum re-examination**

< 0.01

Regular

442 (69.2)

57 (12.9)

385 (87.1)

1

Irregular

155 (24.3)

59 (38.1)

96 (61.9)

4.15

2.71-6.36

None

42 (6.6)

17 (40.5)

25 (59.5)

4.59

2.34-9.03


* The severity of side effects is based on the patient's opinion.

** Regular sputum re-examination: New smear positive cases performing sputum re-examination at the end of the 2nd, 5th and 6th month of the therapy, according to the guidelines.

Ai et al. BMC Public Health 2010 10:112   doi:10.1186/1471-2458-10-112

Open Data